Clinical trial · Observational
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer
Aberrant Expression of Circulating Micro RNA as a Biomarker for Diagnosis of Breast Cancer in Egyptian Females
NCT04720508CI-TRIAL-00049559unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study we aim to: 1. Assess serum miRNA-373, miRNA-425-5p expression in patients with breast cancer. 2. Explore their correlations with breast cancer clinicopathological documented data including staging, grading and tumor receptors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample collection. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A (patient group)
- description
- included 25 patients with BC admitted to department of medical Oncology, South Egypt Cancer Institute, Assiut University. blood samples will be obtained after getting informed consent.
- interventionNames
- Diagnostic Test: blood sample collection.
- label
- Group B (control group)
- description
- included 25 controls age-matched , sex-matched and apparently healthy. blood samples will be obtained after getting informed consent .
- interventionNames
- Diagnostic Test: blood sample collection.
Primary outcomes (1)
- measure
- Assess serum miRNA-373 and miRNA-425-5p expression in patients with breast cancer.
- timeFrame
- baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Female age 20 years or older * documented diagnosis of breast cancer based on physical examination, imaging and histopathology * possibility of obtaining blood samples from the subject. Exclusion Criteria: * All patients with prior history of exposure to chemotherapy, radiotherapy or hormonal therapy . * patients with other malignancies. * patients with chronic inflammatory diseases. * patients with missed documentation for histopathological diagnosis of breast cancer.
References
Publications (14)
- BACKGROUNDIbrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. Epub 2014 Sep 21. PMID 25328522
- BACKGROUNDYalcin B. Staging, risk assessment and screening of breast cancer. Exp Oncol. 2013 Dec;35(4):238-45. PMID 24382431
- BACKGROUNDAutier P, Boniol M. Mammography screening: A major issue in medicine. Eur J Cancer. 2018 Feb;90:34-62. doi: 10.1016/j.ejca.2017.11.002. Epub 2017 Dec 20. PMID 29272783
- BACKGROUNDMatsen CB, Neumayer LA. Breast cancer: a review for the general surgeon. JAMA Surg. 2013 Oct;148(10):971-9. doi: 10.1001/jamasurg.2013.3393. PMID 23986370
- BACKGROUNDAalami AH, Pouresmaeil V, Amirabadi A, Mojahed FH, Rad MQ, Sahebkar A. Evaluation of the Diagnostic Properties of Serum hsa-miR-223-5p in the Detection of Gastric Cancer: A Case-Control Study. Anticancer Agents Med Chem. 2020;20(7):800-808. doi: 10.2174/1871520620666200204100602. PMID 32013852
- BACKGROUNDZhou Y, Sheng B, Xia Q, Guan X, Zhang Y. Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer. Cancer Gene Ther. 2017 Aug;24(8):317-324. doi: 10.1038/cgt.2017.20. Epub 2017 Aug 11. PMID 28799568
- BACKGROUNDEichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem. 2013 Oct;59(10):1489-96. doi: 10.1373/clinchem.2013.205161. Epub 2013 Jun 7. PMID 23748853
- Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV, Sanz JM, Passaro A, Pedriali M, Frassoldati A, Querzoli P, Sabbioni S, Carcoforo P, Hollingsworth A, Negrini M. Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res. 2015 Jun 6;3:12. doi: 10.1186/s40364-015-0037-0. eCollection 2015.